Basket | Login | Register

 
 
 
 

Lithuania

Reimbursement of anti-dementia drugs

The availability of medicines in general

Medicines in Lithuania are fully covered for children under 18, persons with group 1 disability and for hospital treatment. 50% of the price of medicines is covered for old-age pensioners, persons with group 2 disability and other persons entitled to a social insurance protection.

Finally, the Lithuanian system prescribes reimbursement levels for medicines for specific diseases on a special list for which reimbursement can be 50%, 80%, 90% or 100% depending on the disease. [1]

The availability of Alzheimer treatments

In Lithuania, only donepezil and memantine are part of the reimbursement system. People with an MMSE score between 20 and 0 can qualify for the reimbursement of donepezil. The same information for memantine was not available. There are no restrictions in Lithuania for the reimbursement of these treatments for people living alone or in nursing homes.

Alzheimer Europe has no information on whether there are special requirements in Lithuania as to which doctors can prescribe Alzheimer treatments.

 

Donepezil

Rivastigmine

Galantamine

Memantine

Reimbursement

Yes

No

No

Yes

Initial treatment decision

No information

N/A

N/A

No information

Continuing treatment decision

No information

N/A

N/A

No information

Required examinations

MMSE

N/A

N/A

No information

MMSE limits

20-0

N/A

N/A

No information

People living alone

No restrictions

N/A

N/A

No restrictions

People in nursing homes

No restrictions

N/A

N/A

No restrictions

[1] European Commission (2006): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland : Comparative tables

 

 
 

Last Updated: mercredi 15 juillet 2009

 

 
 

Options

  • Send this page to a friend